Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Q: Attractions such as the Louvre Abu Dhabi museum and the Ferrari World theme park will be closed from March 15-31, the Abu Dhabi Government Media Office said, while the country’s civil aviation authority indefinitely suspended flights to and from Lebanon, Turkey, Syria and Iraq from March 17. The UAE, which has reported 85 coronavirus infections but no deaths, and other Gulf Arab states are intensifying measures to halt the virus as the number of cases rises. Saudi Arabia and Kuwait have taken the most drastic steps, cancelling all international flights. Dubai, the UAE’s regional business and transit hub, said it was cancelling all events planned in March and asked hotels to stop hosting wedding celebrations. Some shops have voluntarily closed to boost containment efforts. In the capital, Abu Dhabi, cinemas, arcades and entertainment venues have been shuttered, state news agency WAM reported. Seeking to soften the impact of the shutdowns on key sectors such as tourism and transportation, the central bank said its program would help banks and companies weather the crisis. Saudi Arabia also announced $13 billion to support small and medium enterprises. Saudi Arabia, which reported 17 new cases on Saturday bringing its total to 103, said two-week flight suspensions would start on Sunday, while Kuwait did not specify a length for its grounding which began on Saturday. Saudi Arabia has already suspended the Umrah pilgrimage and locked down its eastern Qatif region where many infections are located. On Saturday, it also closed popular family entertainment zones located inside many shopping malls. Health ministry spokesman Mohammed Abdelali urged the population of 30 million to avoid gathering in public, minimize movements and stay at home as much as possible. “(Such) measures slow the growth of cases so that we can control it, while the countries that take delayed measures experience fast growth which the health systems cannot deal with,” he told reporters. The Gulf Cooperation Council (GCC), a group of six oil-rich Arab monarchies which also includes Qatar, Bahrain and Oman, has reported nearly 900 coronavirus cases, mostly in people who had traveled to Iran or who been infected by visitors to Iran. No deaths have been reported in the GCC, unlike Iran where the toll rose by nearly 100 on Saturday to 611, out of 12,729 total infections. Oman, with the lowest number of infections in the region at 20, said on Saturday all schools and educational institutions would close for a month, a precaution also taken by other GCC states and Yemen. Saudi Arabia and Oman canceled all sporting events until further notice, state media said. The UAE will stop issuing visas, except for foreign diplomats, from March 17, WAM reported, citing immigration authorities. Qatar will halt the issuance of visas upon arrival to a number of European nationalities from Sunday, the government communication office said, while the Qatar Olympic Committee suspended all local sports activities until March 29. Qatar confirmed 17 new infections on Saturday, bringing the total number of cases to 337, the highest in the GCC, followed by Bahrain with 211 and Kuwait with 104. Gulf health authorities have stepped up pleas to avoid gatherings and are sanitizing public places. Police in Kuwait used drones fitted with loudspeakers to urge people on the streets to avoid gathering. Health Minister Basel Al-Sabah said on state television: “I urge you by God to stay at home.”  The competing sides in Yemen’s civil war announced airport closures including in the capital Sana’a, a measure that will affect flights operated by United Nations organizations taking part in humanitarian relief efforts.

A: UAE cancels events, flights as central bank announces coronavirus fiscal plan.
****
Q: Biotechnology company Alkermes said earlier in the day that  it expected Lilly to drop out of their program to develop an  inhaled insulin treatment for diabetes, sending Alkermes shares  down more than 9 percent. Lilly’s decision marks the third setback in recent months  for inhaled insulin formulations, once deemed potential  blockbuster products because of their greater convenience than  standard injectable insulin. Cambridge, Massachusetts-based Alkermes, which makes the  alcohol addiction drug Vivitrol, said Lilly has the right to  terminate its license to the inhaled treatment, Air Insulin, at  its discretion. “While Lilly may elect not to commercialize Air Insulin,  Alkermes believes that the phase 3 safety and efficacy trials  should be completed,” Alkermes said in a statement. After Lilly’s announcement, the company said it was  evaluating the impact of the termination, which will become  effective in 90 days. Indianapolis-based Lilly said its decision was not due to  safety concerns, “but rather was a result of increasing  uncertainties in the regulatory environment, and a thorough  evaluation of the evolving commercial and clinical potential of  the product compared to existing medical therapies.”    Lilly Chief Operating Officer John Lechleiter said in a  statement that the company is beginning the process of halting  ongoing clinical studies. Lilly said it will record a first-quarter 2008 charge of  around $90 million to $120 million, or 5 cents to 7 cents per  share. The company said its adjusted earnings per share outlook  remains unchanged at $3.85 to $4.00, while net earnings will  range from $3.73 to $3.90. Lilly’s action comes just five months after Pfizer Inc  abandoned Exubera, the first approved inhaled form of insulin,  and returned rights to the product to longtime partner Nektar  Therapeutics. Exubera had dismal sales because patients were turned off  by the clumsy device used to administer the powdered insulin  and because doctors were concerned by the drug’s tendency to  slightly impair lung function. Alkermes Chairman Richard Pops, in an interview with  Reuters in October, said Air Insulin may have similar effects  on lung function. “We’re assuming that pulmonary insulins in that regard are  all pretty much the same,” he said, although a conclusive  picture of Air Insulin’s safety will not emerge until two-year  safety trials of the product end later this year. A second setback for inhaled insulin came in January, when  Novo Nordisk said it was halting development of its AERx  product, meant to deliver inhaled droplets. The Danish  drugmaker said AERx did not have adequate sales potential,  given the limited commercial success seen with Exubera. Morgan Stanley analyst Jami Rubin said on Friday Lilly’s  abandonment of AIR Insulin made good business sense. “We are not (at) all surprised, and have never been strong  advocates of the pulmonary insulin agents, following the poor  launch and ultimate demise of Pfizer and Nektar’s Exubera and  Novo Nordisk’s termination of its AERx program,” Rubin said in  a research note. Rubin said Alkermes, known for its drug-delivery  technology, is unlikely to continue development of Air Insulin  without Lilly, “given that this represents the third  termination of a pulmonary insulin drug.”    But she said the sharp drop in Alkermes shares represented  a buying opportunity for investors because Air Insulin had only  paltry sales potential. She said investors should be focused instead on another  product Alkermes is developing with Lilly: a long-acting  formulation of Lilly’s Byetta diabetes treatment called Byetta    “We estimate that Byetta LAR could be worth $11 to $12 for  the (Alkermes) stock,” Ryan said. Alkermes shares fell $1.14 to close at $11.26 on Nasdaq. Lilly, a far larger company with an array of big-selling  products, rose 2 cents to end at $49.70 on the New York Stock  Exchange, and was slightly lower at $49.67 in after-hours  trading.

A: Eli Lilly drops inhaled insulin program.
****
Q: An electron micrograph of a negatively stained human papilloma virus. REUTERS/National Cancer Institute/Handout Despite an overall slight decline in head and neck cancers in recent years, cases of a particular form called oropharyngeal squamous cell carcinoma (OSCC) have increased sharply, particularly in the developed world. This growth seems to be linked to cancers caused by the human papillomavirus (HPV), scientists said in a report in the British Medical Journal. Two vaccines — Cervarix, made by GlaxoSmithKline, and Gardasil, made by Merck & Co — can prevent HPV, which causes virtually all cases of cervical cancer, the second most common cancer in women worldwide. Many rich nations have launched HPV immunisation programs for girls to try to protect them from the common sexually transmitted virus before they become sexually active. The scientists, led by Hisham Mehanna of the Institute of Head and Neck Studies at University Hospital Coventry, said while including boys in immunisation plans has been seen as too expensive, it may be time to look again. “We need to look at the evidence again to re-evaluate the cost-effectiveness of male children in light of this new and rapidly rising incidence,” he said in an interview. Analyst Savvas Neophytou at Panmure Gordon in London said such studies would dispel worries about sales prospects for HPV vaccines, and repeated his ‘buy’ recommendation for Glaxo stock. “The emergence of new data such as this may increase motivation amongst national vaccination authorities worldwide to re-double efforts to vaccinate children before they become sexually active,” he said in an equity research note. Glaxo shares were slightly lower, in line with a weaker European pharmaceutical sector and down 0.4 percent by 0905 GMT. More than 500,000 cases of cervical cancer are diagnosed annually in women and it kills around 200,000 a year. Head and neck cancer is the sixth most common cancer among men and women, with about 640,000 new cases each year worldwide. A recent study found the risk of developing oropharyngeal carcinoma was linked to a history of six or more lifetime sexual partners, four or more lifetime oral sex partners, and, for men, an earlier age at first sexual intercourse. “Sexual transmission of HPV — primarily through orogenital intercourse — might be the reason for the increase in incidence of HPV related oropharyngeal carcinoma,” wrote Mehanna. The scientists pointed to recent studies which showed a 70 percent increase in the detection of HPV in biopsies taken to diagnose oropharyngeal carcinoma in Stockholm since the 1970s. HPV-related cancer was also reported in 60-80 percent of recent biopsy samples in studies in the United States, compared with 40 percent in the previous decade, they wrote. Mehanna said the findings had other important health implications. Patients with HPV-related head and neck cancers were typically younger and employed, he said, and because their tumors appeared to be less deadly than those caused by factors like smoking and drinking, patients may also live longer with the physical and psychological effects of treatment. “This means they would need prolonged support from health, social, and other services, and may require help in returning to work,” he said.

A:
Sex virus blamed for rise in head and neck cancers.
****